Loading cancer entity…
Loading cancer entity…
Clinical trials
10,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,643)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06484920 | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | recruiting | Phase 2 | 24 | Rita AssiOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03458520 | Pediatric PET/MR Image Registry | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03758989 |
| A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma |
| recruiting |
| Phase 2 |
| 40 |
| University of RochesterOTHER |
| 1 |
| Feb 9, 2026 |
| clinicaltrials |
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) | recruiting | Phase 1 / Phase 2 | 63 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04368702 | CONFIRM: Magnetic Resonance Guided Radiation Therapy(CONFIRM) | recruiting | N/A | 70 | Brigham and Women's HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04883437 | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | recruiting | Phase 2 | 49 | Emory UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06280924 | Prehab Prior to Stem Cell Transplantation in Multiple Myeloma(MOTIVATE) | recruiting | N/A | 30 | University of AlbertaOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 3 | 394 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05093335 | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05425992 | Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families | recruiting | — | 20 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06574568 | A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 70 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389616 | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | recruiting | Phase 2 / Phase 3 | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07390071 | Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy | recruiting | N/A | 40 | University of UtahOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05800405 | Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Early Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05892718 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | recruiting | Phase 1 | 80 | FBD Biologics LimitedINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
| NCT07278921 | Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).(MosuOSSHSR) | recruiting | — | 25 | Andrés José Maria FerreriOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05180097 | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 84 | Canadian Cancer Trials GroupNETWORK | 2 | Feb 2, 2026 | clinicaltrials |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 396 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07114939 | FTT PET/CT in Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07381738 | Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT04669171 | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma(SIDNEY) | recruiting | Phase 1 / Phase 2 | 80 | EnteromeINDUSTRY | 4 | Jan 30, 2026 | clinicaltrials |
| NCT05839210 | Lifestyle Intervention of Food and Exercise for Lymphoma Survivors(LIFE-L) | recruiting | N/A | 140 | University of MiamiOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06357676 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | recruiting | Phase 1 / Phase 2 | 27 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06829771 | Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07114367 | NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma(POTENTIAL-M) | recruiting | Phase 1 | 9 | NOBO MedicineINDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | recruiting | Phase 3 | 292 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04240054 | Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency(VICD) | recruiting | Phase 2 | 41 | Medical College of WisconsinOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04670874 | Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29 | recruiting | — | 1,250 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05371132 | Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06371768 | Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors(AYA STEPS) | recruiting | N/A | 260 | Duke UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06484985 | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. | recruiting | Phase 1 | 78 | Axter Therapeutics (Beijing) Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07368270 | Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 30 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371923 | Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 50 | Beijing Tongren HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07372352 | Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL | recruiting | Phase 2 | 26 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07372365 | Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. | recruiting | Phase 2 | 23 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06069830 | PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma(ENKTL) | recruiting | N/A | 89 | Ruijin HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369895 | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 18 | O&D BioTech Group CO., LimitedINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05921253 | Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy(OU-SCC-NCAN) | recruiting | Early Phase 1 | 104 | University of OklahomaOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT00582621 | Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | recruiting | — | 500 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06326463 | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | recruiting | Phase 1 | 18 | St. Jude Children's Research HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06693830 | ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL | recruiting | N/A | 40 | Hua-Jay J Cherng, MDOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06846463 | Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ | recruiting | Phase 2 | 21 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | recruiting | — | 5,000 | MPN Research FoundationOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05706766 | Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05898477 | Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis | recruiting | — | 2,000 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06357754 | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | recruiting | — | 50 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 22, 2026 | clinicaltrials |
| NCT07044427 | Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients(Myfall) | recruiting | N/A | 60 | University Hospital HeidelbergOTHER | 1 | Jan 22, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Feb 10, 2026source: clinicaltrials